





UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1459 Alexandria, Vignina 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.		
09/657,431	09/07/2000	Dominique P. Bridon	REDC-2201 USA	1545		
20872 75	90 06/17/2003					
	& FOERSTER LLP	EXAMINER				
425 MARKET SAN FRANCIS	STREET SCO, CA 94105-2482		CHISM, E	CHISM, BILLY D		
			ART UNIT	PAPER NUMBER		
,			DATE MAILED: 06/17/2003			

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No	о.	Applicant(s)			
Office Action Summary		09/657,431 BRIDON ET AL.					
		Examiner		Art Unit			
		B. Dell Chism	<u></u>	1654			
The MAILING DATE of this con Period for Reply	nmunication app	ears on the cov	er sheet with the c	orrespondence ad	ldress		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status							
1) Responsive to communication	(s) filed on <u>02 A</u>	<i>pril 2003</i> .					
2a) ☐ This action is FINAL.	2b)⊠ Thi	s action is non-	final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. Disposition of Claims							
4)⊠ Claim(s) <u>1-16 and 19-21</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5)⊠ Claim(s) <u>10-12 and 19-21</u> is/are allowed.							
6)⊠ Claim(s) <u>1-9 and 13-16</u> is/are rejected.							
7)⊠ Claim(s) <u>3-5</u> is/are objected to.							
8) Claim(s) are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120			511000440()	(1)			
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
 Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
14)☐ Acknowledgment is made of a cla	im for domestic	priority under 3	35 U.S.C. § 119(e)	(to a provisional	application).		
a) ☐ The translation of the foreig 15)☐ Acknowledgment is made of a cla	n language prov aim for domestic	risional applicat priority under :	ion has been rece 35 U.S.C. §§ 120	ived. and/or 121.			
Attachment(s)							
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Reviews Notice of Draftsperson's Patent Drawing Reviews Notice of Draftsperson's Patent Drawing Reviews Notice of References Cited (PTO-892)	ew (PTO-948) 49) Paper No(s) <u>10</u>	4) 5) 6)		(PTO-413) Paper No(satent Application (PTC			
J.S. Patent and Trademark Office PTO-326 (Rev. 04-01)	Office Acti	on Summary		Part of Paper No. 15			



Application/Control Number: 09/657,431

Art Unit: 1654

DETAILED ACTION

This Office Action is in response to Paper No. 14, filed 02 April 2003, wherein Applicants have canceled the response file 18 March 2003, pursuant to discussions with the Examiner on 01 April 2003, and replace the response with the response of Paper No. 14. Claims 1-16 and 19-21 are under consideration. Claims 17-18 are canceled.

Information Disclosure Statement

The Information Disclosure Statement has been considered. The request for a replacement IDS is withdrawn and copies were located.

Withdrawal of Objections and Rejections

The rejections and/or objections made in the prior office action filed on 19 November 2002, which are not explicitly stated below, in original or modified form are withdrawn.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Claim Objections

1. Claims 3-5 are objected to because of the following informalities: claims 3-5 are dependent claims that further limit the parent claims, thus, the use of "A" to refer to the kringle 5 peptide of the claims from which they depend, is improper and the word "A" should be deleted and "The kringle 5 peptide." Appropriate correction is required.



Application/Control Number: 09/657,431

Art Unit: 1654

Claim Rejections - 35 USC § 112

2. Claims 1-9 and 13-16 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1-4 are rejected for the indefinite recitation of "modified" and "derivative" wherein it is unclear if the claimed invention is a "modified" peptide or a peptide "derivative."

Claims 5-6 are rejected for depending from rejected claims.

Claim 7 is rejected for the indefinite recitation of the phrase "or analog thereof," wherein it is unclear if the claim is drawn to an analog of the peptide derivative or if the claim is drawn to both a derivative of the peptide and an analog of the peptide.

Claims 8-9 are rejected for depending from rejected claim 7.

Claim 13 is rejected for the indefinite recitation of the phrase "treating angiogenesis."

The claims are drawn to anti-angiogenesis compounds, however, claim 13 reads as if treating angiogenesis is inhibiting or reducing angiogenesis and enhancing or stimulating angiogenesis.

The claim should be amended to read as the compound is for the inhibition or reduction of angiogenesis in patients in need thereof.

Claims 14-16 are rejected for depending from rejected claim 13.

Conclusions

Claims 3-5 objected to, and claims 1-9 and 13-16 are rejected. Claims 10-12 and 19-21 are free of the prior art and allowable.



Application/Control Number: 09/657,431

Art Unit: 1654

Any inquiry concerning this communication or earlier communications from the examiner should be directed to B. Dell Chism whose telephone number is 703-306-5815. The examiner can normally be reached on 7:30 AM - 4:30 PM, Monday through Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached on 703-306-3220. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

B. Dell Chism 16 June 2003

BRENDA BRUMBACK
SUPERVISORY PATENT EXAMINED
TECHNOLOGY CENTER 1500